Multienzyme Complexes Or Mixtures Of Enzymes Patents (Class 424/94.2)
  • Patent number: 10920051
    Abstract: The present invention is a resin composition including: a resin component; zinc oxide; and an acetic acid remover, wherein the resin component includes an ethylene-vinylacetate copolymer and a content of the ethylene-vinylacetate copolymer in the resin component is greater than or equal to 10% by mass, wherein the acetic acid remover is an acid acceptor, a nitrogen-containing aromatic heterocyclic compound having a mercapto group, or a combination thereof, and wherein a mass ratio of the zinc oxide to the ethylene-vinylacetate copolymer is greater than or equal to 0.06 and less than or equal to 0.20.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: February 16, 2021
    Assignee: SUMITOMO ELECTRIC INDUSTRIES, LTD.
    Inventors: Shigeyuki Tanaka, Taro Fujita, Shinya Nishikawa, Takaya Kohori, Motoi Matsuda, Hiroyuki Okawa
  • Patent number: 10894031
    Abstract: Disclosed herein are nutraceutical compositions comprising or consisting essentially of one or more types of polyphenols (e.g., a green tea polyphenol) and one or more types of reactive oxygen species, and methods for their use to treat gastrointestinal conditions, inflammatory conditions, and immune conditions.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: January 19, 2021
    Assignee: PowerGut, INC.
    Inventors: Michael Evans, Robert Wotring
  • Patent number: 10864242
    Abstract: The present invention discloses a composition for the therapeutic management of male sexual dysfunction and related disorders. Specifically, the invention discloses a composition comprising 60-65% w/w Withania somnifera extract, 12-18% w/w Mucana pruriens extract, 5-10% w/w Coleus forskolii extract, 12-18% w/w Kaempferia parviflora extract, 0.1-2% w/w Piper nigrum extract, for use as an aphrodisiac.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: December 15, 2020
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sarang Bani, Anjali Pandey
  • Patent number: 10842179
    Abstract: A method of treating hypercholesterolemia in mammals, by administering an effective amount of a microbial fermentation product, and regulating genes involved in lipoprotein metabolism. A method of regulating cholesterol levels in a patient by administering an effective amount of a composition chosen from the group consisting of PAZ, specific components isolated from PAZ, chemically synthesized analogues of the components of PAZ, and regulating genes involved in lipoprotein metabolism. A method of treating high cholesterol levels in an individual by administering an effective amount of a microbial fermentation product, up-regulating the expression of at least one of the genes that encode ABCA1, ApoA1, and SRB1, and down-regulating the gene that encodes CETP. A method of preventing the onset of high cholesterol levels and/or a deleterious lipoprotein profile in an individual.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: November 24, 2020
    Assignee: Zivo Bioscience, Inc.
    Inventors: Smiti Vaid Gupta, Fazlul H. Sarkar, Andreea Geamanu, Andrew A. Dahl
  • Patent number: 10736946
    Abstract: Compositions and methods for treating or preventing S. aureus infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce S. aureus populations and thereby treat or prevent infection by S. aureus. The compositions include one or more digestive enzymes, e.g., one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: August 11, 2020
    Assignee: GALENAGEN, LLC
    Inventors: Joan M. Fallon, Matthew Heil, James J. Fallon
  • Patent number: 10709746
    Abstract: The present disclosure is a compound, a method of making the compound and method of using such compound preferably in the form of a dietary supplement that, when administered, is capable of supporting memory, focus, and clarity. The unique combination of the composition is preferably administered orally. The composition is preferably comprised of at least Hericium Erinaceus, Bacopa Monnieri, ECGC (Epigallocatechin-3-Gallate), Huperzine, Acetyl-L-Carnitine, Vitamin B12, Ginkgo Biloba, Phosphatidylserine, and Gotu Kola, in pre-determined amounts. The composition can further comprise a palliative agent, and can be provided in the form of a capsule, powder, liquid or tablet.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: July 14, 2020
    Inventor: Suzy Cohen
  • Patent number: 10619140
    Abstract: Provided are compositions and methods for the treatment of hemoglobinopathies such as thalassemias and sickle cell disease. Compositions and methods include one or more endonuclease(s) or endonuclease fusion protein(s), including one or more homing endonuclease(s) and/or homing endonuclease fusion protein(s) and/or CRISPR endonuclease(s) and/or CRISPR endonuclease fusion protein(s): (a) to disrupt a Bcl11a coding region; (b) to disrupt a Bcl11a gene regulatory region; (c) to modify an adult human ?-globin locus; (d) to disrupt a HbF silencing DNA regulatory element or pathway, such as a Bcl11a-regulated HbF silencing region; (e) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; (f) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; and/or (g) to correct one or more ?-globin gene mutation(s).
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: April 14, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Ryo Takeuchi, Mark T Groudine, Barry L. Stoddard, Michael A Bender
  • Patent number: 10568944
    Abstract: Compositions containing bromelain are disclosed for use as topical therapeutic agents for the treatment of rosacea. The compositions include lotions, creams and ointments.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: February 25, 2020
    Inventor: Merry Richon
  • Patent number: 10444311
    Abstract: Techniques for optimizing a magnetic resonance imaging (MRI) protocols are described herein. An example method can include receiving one or more MRI scanner settings for an imaging sequence; selecting at least one objective function from a plurality of objective functions; selecting an acquisition train length; selecting a k-space strategy; selecting one or more imaging parameters; and acquiring a magnetic resonance (MR) image using at least one of an optimized k-space strategy, an optimized acquisition train length, or optimized imaging parameters.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: October 15, 2019
    Assignees: Ohio State Innovation Foundation, Research Institute at Nationwide Children's Hospital
    Inventors: Jinghua Wang, Zhong-lin Lu, Nehal Parikh, Lili He
  • Patent number: 10328129
    Abstract: Provided herein is a composition and a method for treating nucleic acid-related eye disease.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: June 25, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventor: Sandeep Jain
  • Patent number: 10208297
    Abstract: Isolated polypeptides with lipase activity; polynucleotides encoding the polypeptides; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the polypeptides for cleaning are disclosed.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: February 19, 2019
    Assignee: Novozymes A/S
    Inventors: Ming Li, Tianqi Sun, Xianzhi Jiang, Lone Baunsgaard, Carsten Hoerslev Hansen, Kim Borch, Han Bucong
  • Patent number: 10195256
    Abstract: Disclosed is a formulation of the following enzymes: Beta Glucanase, Chymotrypsin, Phytase, Lactase, and Invertase, which has been found to be effective in treating salicylate intolerant people, and causing a significant improvement in a wide variety of pathologies and symptoms, including, but not limited to: acid reflux disease, stuttering, migraines, ADHD, behavioral deficits, Tourettes disease, seizures, autism (ASD), atrial fibrillation, anxiety, depression, joint pain, cognitive and perceptual disorders, respiratory difficulties and non-diabetic neuropathy. The formulation is also for treating or reducing intolerance of gluten, corn or soy.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: February 5, 2019
    Inventor: Thea Fournier
  • Patent number: 10183064
    Abstract: The present disclosure provides a delivery system comprising (i) a physiologically acceptable carrier and (ii) a proteolytic enzyme or effector thereof for use in a method for relaxing fibers within a subject's oral cavity. In some embodiments, the relaxation is for use in tooth manipulation (particularly repositioning). In some embodiments, the method involves the use of the proteolytic enzyme or effector thereof at a concentration effective to cause relaxation of fibers between the tooth's alveolar bone and gingiva while maintaining integrity of the fibers surrounding the tooth. Also disclosed herein are methods for fiber relaxation and/or repositioning of tooth making use of the proteolytic enzyme or effector thereof.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: January 22, 2019
    Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Avraham D. Schroeder, Assaf Yosef Zinger, Avishay Herman
  • Patent number: 10159721
    Abstract: The present document describes an enzyme formulation comprising an enzyme mixture comprising from about 5% to about 45% (wt/wt) of a fungal protease enzyme; and from about 1.5% to about 50% (wt/wt) of at least one polysaccharide digesting enzyme; in combination with an acceptable pharmaceutical carrier. The present document also describes the use of the formulation of the present invention for the prevention or treatment of digestive disorder.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: December 25, 2018
    Inventor: Bryan Christopher Farnum
  • Patent number: 10155938
    Abstract: A composition used in targeted mutagenesis is provided, which includes a first expression cassette comprising a nucleotide sequence which encodes a CAS9 endonuclease; a second expression cassette comprising a nucleotide sequence which encodes a guide RNA sequence, wherein the guide RNA sequence is complementary to a target genome nucleotide sequence in a cell; and a third expression cassette comprising a nucleotide sequence which encodes a Trex2 exonuclease (Trex2) gene. The first, second, and third expression cassettes may be a part or a portion of one or more expression vectors.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: December 18, 2018
    Assignee: CITY OF HOPE
    Inventors: Jeremy M. Stark, Diana Yanez
  • Patent number: 10123959
    Abstract: The invention relates to the discovery that collagenase injections are effective in dissolving and lysing the collagenase septa network in the skin that comprises cellulite. As such, the invention relates to methods of treating cellulite in a patient in need of such treatment comprising injecting or otherwise delivering the effective amount of purified collagenase to the collagenase septa network of cellulite in the skin. The invention also relates to the use of collagenase in the manufacture of a medicament to treat cellulite of the skin.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: November 13, 2018
    Assignee: The Research Foundation for The State University of New York
    Inventors: Marie A. Badalamente, Alexander B. Dagum
  • Patent number: 10112989
    Abstract: The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, gpIb and/or collagen, homologs of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: October 30, 2018
    Assignee: Ablynx, N.V.
    Inventor: Karen Silence
  • Patent number: 10092022
    Abstract: The present invention relates to compositions and their uses, specifically provides supplements for equines, in particular horses and ponies. Such a composition is ideal for horses and ponies where encouraging a more energetic performance is required.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: October 9, 2018
    Assignee: Mars, Incorporated
    Inventors: Patricia Harris, Verity Beaton, Clare Barfoot
  • Patent number: 10006052
    Abstract: Disclosed herein are compositions for inactivating the human CCR5 gene comprising engineered LAGLIDADG homing endonucleases (LHEs) and their derivatives, particularly derived from members of the \-Onul subfamily of LHE. Polynucleotides encoding such endonucleases, vectors comprising said polynucleotides, cells comprising or having been treated with such endonucleases, and therapeutic compositions deriving therefrom are also provided.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: June 26, 2018
    Assignees: CELLECTIS, PRECISION GENOME ENGINEERING, INC.
    Inventors: Jordan Jarjour, Alexander Astrakhan
  • Patent number: 9943599
    Abstract: The present inventors have shown that electroporation with calcium ions are efficient on cutaneous and subcutaneous nodules. In particular the present inventors here disclose that a solution comprising calcium ions (Ca2+) with a concentration of at least 0.1 M is extremely useful in a method of treating a neoplasm, such as cancer with means for causing transient permeabilization of the cell membranes of at least part of the neoplasm before, during and/or after administration of said solution, wherein said solution is administered with a ratio of 0.2 to 0.8 of the volume of said part of the neoplasm.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: April 17, 2018
    Assignee: HERLEV HOSPITAL
    Inventors: Karen Julie Gehl, Stine Krog Frandsen, Jens Ole Eriksen, Hanne Margrethe Gissel Hyldkrog, Pernille Højman Jensen
  • Patent number: 9931302
    Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: April 3, 2018
    Assignee: Curemark , LLC
    Inventors: Joan M. Fallon, Matthew Heil
  • Patent number: 9895463
    Abstract: Fragrance control is provided by articles of manufacture including various solid state fragrancing objects, methods of using such objects, and systems that employ one or more such objects. The solid state fragrancing object can be used to inconspicuously provide fragrance to a user in an environment by disposing the solid state fragrancing object in the environment and configuring the solid state fragrancing object as at least a portion of a fixture within the environment. The fragrancing object can be easy to manufacture, long lasting, provide fragrance that is consistently released over time, provide an indication to the user that the object needs to be replaced, and can hold a desired ratio of fragrance.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: February 20, 2018
    Assignee: IMPACT PRODUCTS, LLC
    Inventors: John T. Irwin, Stephen A. Dukes, Robert James Hayes, Donald James Staufenberg, Jeffrey C. Gayer
  • Patent number: 9770494
    Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: September 26, 2017
    Assignee: ThromboGenics NV
    Inventors: Steve Pakola, Marc De Smet
  • Patent number: 9738883
    Abstract: The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium Vibrio alginolyticus chemovar. iophagus (NCIMB Number: 1 1038, synonym LMG 3418, hereinafter called Vibrio alginolyticus), which said process provides high production levels of collagenase with a stable, reproducible, cheap fermentation process. The collagenase produced from Vibrio alginolyticus according to the process described herein also presents a specific activity superior to that of other microbial collagenases, is stable in aqueous solution, and can be frozen without significant damage.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: August 22, 2017
    Assignee: FIDIA FARMACEUTICALS S.P.A.
    Inventors: Susanna Vaccaro, Michele Caputo, Christian Cuppari, Giovanni Gennari
  • Patent number: 9714456
    Abstract: Pharmaceutical compositions comprising spray-dried oxalate decarboxylase crystals are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using compositions comprising spray-dried oxalate decarboxylase crystals are also disclosed.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: July 25, 2017
    Assignee: Allena Pharmaceuticals, Inc.
    Inventors: Jack Greene, Richard Johnson, Dennis Krushinskie, Bhami Shenoy
  • Patent number: 9688773
    Abstract: The invention provides a product combination or composition, and also multispecific antibodies comprising two or more antigen-binding sites (as antibodies or antigen binding fragments thereof), wherein two the antigen-binding bind to distinct non-overlapping epitopes of the human c-Met protein. The product combination or composition or multispecific antibody inhibits HGF-independent activation of the human c-Met receptor protein.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: June 27, 2017
    Assignee: ARGEN-X N.V.
    Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
  • Patent number: 9682131
    Abstract: A process for the endogenic catabolism of homocysteine and the control of homocysteine levels for treating disease and the degenerative diseases of aging is provided along with pharmaceutical compositions having thioretinamide, retinol or combinations thereof in combination with an enzyme or a pro-enzyme. The process includes the catabolism of homocysteine thiolactone in cells and tissues by catalyzing the reaction of homocysteine thiolactone with an enzyme-bound retinoic acid to increase the bioavailability of thioretinamide in diseased and aged cells and tissue.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: June 20, 2017
    Inventor: Kilmer S. McCully
  • Patent number: 9592280
    Abstract: A debridement enzyme for necrotic tissue is described that is not dependent upon proteolytic enzymatic activity but instead utilizes the amylase family of enzymes. The amylases (?-, ?-, ?-amylase) are noted for the cleavage of the ?-glycosidic bonds of polysaccharides, yielding lower molecular weight carbohydrate/sugar fragments. It has now been found that ?-amylase is effective in the debridement of devitalized tissue.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: March 14, 2017
    Assignee: ROCHAL INDUSTRIES LLC
    Inventors: Joseph Charles Salamone, Kelly Xiaoyu Chen Leung, Ann Beal Salamone, Katelyn Elizabeth Reilly
  • Patent number: 9592211
    Abstract: A composition comprising alpha-ketoglutaric acid or a pharmaceutically acceptable salt thereof (AKG), and one or more enzymes selected from a group consisting of a lipase, a protease and an amylase, and medical uses thereof in, neurological and/or neurodegenerative disease, neurological trauma, depression or chronic fatigue syndrome.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: March 14, 2017
    Inventor: Stefan Pierzynowski
  • Patent number: 9511126
    Abstract: The present invention relates to a proteolytic extract obtained from bromelain for the treatment of connective tissue diseases. In particular, the present invention relates to a pharmaceutical composition that includes proteolytic extract obtained from bromelain for the treatment of diseases such as Dupuytren's disease and Peyronie's disease.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: December 6, 2016
    Assignee: MediWound Ltd.
    Inventors: Lior Rosenberg, Guy Rubin, Eilon Asculai
  • Patent number: 9511125
    Abstract: A method to treat Influenza, and more particularly Influenza A Virus Subtype H1N1, with the use of a pharmaceutical composition comprising one or more digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes, is disclosed. The method includes the use of an individual's fecal chymotrypsin level as an indicator e.g., biomarker of whether an individual may be more susceptible to Influenza, e.g., Influenza A Subtype H1N1, and/or whether an individual will benefit from administration of the described pharmaceutical compositions. Use of the compositions as sanitizers, antiseptics, disinfectants, and detergents, e.g., to reduce or eradicate influenza virus present on living or inanimate surfaces is also contemplated.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: December 6, 2016
    Assignee: CUREMARK LLC
    Inventors: Joan M. Fallon, Matthew F. Heil, James J. Fallon, James Szigethy
  • Patent number: 9492515
    Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: November 15, 2016
    Assignee: CUREMARK, LLC
    Inventors: Joan M. Fallon, Matthew Heil, James Szigethy, James Fallon
  • Patent number: 9353300
    Abstract: Adhesives made from phosphorylated legume and oil seed flours are described. The adhesive composition includes water and a legume and/or oil seed flour in which at least a portion of ?-amino moieties in lysine residues present in the flour are phosphorylated. An oxidizing agent may also optionally be added to the adhesive composition.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: May 31, 2016
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Srinivasan Damodaran, Dani Zhu
  • Patent number: 9320759
    Abstract: Methods and compositions for treating, reducing, or preventing deterioration of at least one component of the visual system of an animal are disclosed. The methods comprise administering to the animal a composition comprising UFA and NORC in an amount effective to treat, reduce, or prevent deterioration of at least one component of the visual system. Methods extending the prime years of an animal's life, improving the quality of life, and promoting health and wellness of an animal using compositions comprising UFA and NORC are also disclosed.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: April 26, 2016
    Assignee: Nestec S.A
    Inventor: Yuanlong Pan
  • Patent number: 9267128
    Abstract: Gluten-degrading proteases derived from insects, including flour beetles, are isolated, and the purified, and recombinant forms can be used to make gluten-containing food safe for patients suffering from gluten intolerance.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: February 23, 2016
    Assignee: Alvine Pharmaceuticals, Inc.
    Inventor: Pawan Kumar
  • Patent number: 9216209
    Abstract: A process for the endogenic catabolism of homocysteine and the control of homocysteine levels for treating disease and the degenerative diseases of aging is provided along with pharmaceutical compositions having thioretinamide, retinol or combinations thereof in combination with an enzyme or a pro-enzyme. The process includes the catabolism of homocysteine thiolactone in cells and tissues by catalyzing the reaction of homocysteine thiolactone with an enzyme-bound retinoic acid to increase the bioavailability of thioretinamide in diseased and aged cells and tissue.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: December 22, 2015
    Inventor: Kilmer S. McCully
  • Patent number: 9169496
    Abstract: Described is a method for the enzymatic production of butadiene which allows to produce butadiene from crotyl alcohol. Also described are enzyme combinations and compositions containing such enzyme combinations which allow the enzymatic conversion of crotyl alcohol into butadiene. Furthermore, the invention relates to microorganisms which have been genetically modified so as to be able to produce butadiene from crotyl alcohol. Moreover, the invention relates to a method for the enzymatic production of crotyl alcohol from crotonyl-Coenzyme A. The obtained crotyl alcohol can be further converted into butadiene as described herein. Also described are enzyme combinations which allow to convert crotonyl-Coenzyme A into crotyl alcohol as well as (micro)organisms which express such enzyme combinations.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: October 27, 2015
    Assignee: Scientist of Fortune, S.A.
    Inventor: Philippe Marliere
  • Patent number: 9169329
    Abstract: The present invention relates to antibodies that specifically bind to unprocessed c-Met present on the surface of tumor cells. These antibodies are useful in the diagnosis and treatment of cancer or as agents for delivering moieties to cancer cells. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: October 27, 2015
    Assignees: Ludwig Institute for Cancer Research, Monash University
    Inventors: Terrance Grant Johns, Ermanno Gherardi, Andrew Mark Scott
  • Patent number: 9149513
    Abstract: Methods for treating male sub-fertility by administering a pharmaceutical composition to a subject in need thereof are provided. The pharmaceutical compositions include an agent that causes a reduction in an effect of extracellular DNA on sperm cells. The agent may be, for example, an enzyme that degrades DNA such as DNase, a substance that blocks the interaction between cell free DNA and sperm cell surface receptors, a substance that binds to DNA, a substance that inhibits endogenous sperm cell DNase, a substance that inhibits a member of a signal transduction pathway mediated by DNA binding to sperm cell surface receptors, or an agent that stimulates production of an endogenous substance that causes a reduction in an antifertility effect of cell free DNA on sperm cells.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: October 6, 2015
    Assignee: PERINESS LTD.
    Inventors: Benjamin Bartoov, Ronen Yehuda, Melamed Dobroslav
  • Patent number: 9057081
    Abstract: The present invention relates to cell wall degradative systems, in particular to systems containing enzymes that bind to and/or depolymerize cellulose, hemicellulose and other carbohydrates. These systems have a number of applications.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: June 16, 2015
    Assignee: Aemetis Technologies, Inc.
    Inventors: Steven Hutcheson, Ronald Weiner
  • Patent number: 9040040
    Abstract: Tissue fixed charge density (FCD) is identified as another potential therapeutic target for reducing brain tissue swelling. Reduction of the FCD could reduce the thermodynamic force driving water entry into the brain. The present invention discloses chondroitinase ABC (ChABC) reduces tissue FCD and reduces tissue swelling, indicating that it may be an effective treatment to reduce edema and control intracranial pressure.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: May 26, 2015
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Benjamin Simon Elkin, Barclay Morrison, III, John Desmond Finan
  • Publication number: 20150132273
    Abstract: A nutritional supplement that contains folinic acid, folic acid, USP, methylfolic acid, cobalamin, magnesium, docosahexaenoic acid, phosphatidylcholine-docosahexaenoic acid, phosphatidylethanolamine-docosahexaenoic acid. A nutritional supplement is disclosed for the treatment of cognitive disorders, attention deficit disorder, oxidative stress, depression, memory loss, anxiety, and apathy.
    Type: Application
    Filed: December 30, 2013
    Publication date: May 14, 2015
    Inventor: Rhett Sean Daniels
  • Patent number: 9029115
    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: May 12, 2015
    Assignees: Novozymes A/S, Novozymes Inc
    Inventors: Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
  • Publication number: 20150118211
    Abstract: The invention provides methods, compositions, and kits for removal of biofilms from surfaces. The methods described herein comprise simultaneous or sequential application of a perhydrolase enzyme and a mixture of other enzymes, such as proteases, glucanases, esterases, mannanases, phospholipases, cellulases, and/or amylases, to a biofilm on a surface, to effect removal of the biofilm.
    Type: Application
    Filed: November 1, 2013
    Publication date: April 30, 2015
    Applicant: Danisco US Inc.
    Inventors: Christopher C. Barnett, Manoj Kumar, Gregory M. Whited
  • Publication number: 20150118189
    Abstract: The invention relates to the field of microbiology, specifically to a combination of a source of a first enzymatic active domain and a source of a second enzymatic active domain and to a composition comprising said combination. The invention further relates to a composition comprising said combination for use as a medicament, to the use of said composition as an antimicrobial agent and to a method for controlling microbial contamination in a food- or feed product, on and/or in food- or feed processing equipment, on and/or in food- or feed containers.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 30, 2015
    Applicant: MICREOS HUMAN HEALTH B.V.
    Inventors: Martin Johannes Loessner, Fritz Eichenseher
  • Publication number: 20150110765
    Abstract: The present invention relates to isolated polypeptides having alpha-glucuronidase activity, catalytic domains and polynucleotides encoding the polypeptides, catalytic domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides or catalytic domains.
    Type: Application
    Filed: April 22, 2013
    Publication date: April 23, 2015
    Inventors: Johan Börjesson, Anders Vikø-Nielsen, Nikolaj Spodsberg, Kristian Krogh
  • Patent number: 9011842
    Abstract: The present technology relates to an enzyme composition. The enzyme composition may be used to treat gluten intolerant subjects, including suffering from non-Celiac gluten intolerance and/or non-Celiac gluten sensitivity. The enzyme composition may also be used to reduce gluten exposure in certain individuals. For example, the enzyme composition may also be used as a prophylactic to reduce exposure to gluten oligopeptides.
    Type: Grant
    Filed: February 2, 2011
    Date of Patent: April 21, 2015
    Assignees: Amano Enzyme Inc., Amano Enzyme USA Co., Ltd.
    Inventors: James F. Jolly, Horoki Ido, Hirotaka Matsubara, Tetsuya Takahashi, Kyoichi Nishio
  • Patent number: 9011964
    Abstract: A mixed dose of a nanosized drug wherein at least one portion of the mixed dose comprises a core nanosized drug encapsulated in at least one layer of a protective material having the same core drug or different core drug. A mixed dose of a nanosized drug wherein at least one portion of the mixed dose comprises a core nanosized drug encapsulated in at least one shell of a protective material with same drug concentration or different drug concentrations. A mixed dose of a nanosized drug wherein at least one portion of the mixed dose comprises a core nanosized drug encapsulated such that it has different release schedule than other portions of the drug. Methods and systems for manufacturing and administration of nanosized encapsulated drugs are also provided.
    Type: Grant
    Filed: December 6, 2014
    Date of Patent: April 21, 2015
    Inventor: Albert S. Zeng
  • Publication number: 20150104489
    Abstract: The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a combination therapeutic comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a method of treating a mammal suspected of being infected with, or infected with, C. difficile comprising the use of at least deoxyribonuclease; a method of cleaning or sterilising a material or product comprising the use of at least deoxyribonuclease; and a cleaning or sterilising product impregnated with or containing at least deoxyribonuclease.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 16, 2015
    Applicant: London School of Hygiene and Tropical Medicine
    Inventors: Lisa Dawson, Brendan Wren
  • Publication number: 20150098932
    Abstract: Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 9, 2015
    Inventor: Sarah Bacus